Skip to content

ICU Medical ICUI Additional Paid-In Capital

Additional Paid-In Capital at other companies

Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
$1.26B+2.1%
Baxter International logo
Baxter InternationalBAX
$6.21B-1.5%
TFX
TeleflexTFX
$815.81M+4.4%
Medtronic logo
MedtronicMDT
$20.93B+0.4%
Solventum logo
SolventumSOLV
$3.9B+3.0%
Moog Inc. logo
Moog Inc.MOG.A

Other financials

Income statement

See full
Revenue$530.2M-12.3%
Gross profit$206.2M-1.8%
Operating income$13.6M+5.4%
Net income$30.1M+295%
EPS (diluted)$1.20+290%

Balance sheet

See full
Cash & equivalents$288.3M-0.5%
Total debt$1.4B-17.5%
Total equity$2.1B+6.3%
Total assets$4.0B-4.1%

Cash flow

See full
Operating cash flow$38.9M-24.2%
CapEx$11.3M-22.7%
Free cash flow$27.6M-24.8%

Valuation

See full
Market cap$3.39B-6.3%

Profitability

See full
Gross margin37.9%+2.8pp
Operating margin2%-0.7pp
Net margin-0.3%-0.2pp
FCF margin4.2%-1.2pp

Returns & leverage

See full
Return on equity-0.4%-0.2pp
Debt / equity0.6×-0.2×
Current ratio2.3×-0.3×

Where this comes from

Reported directly by ICU Medical in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: ICU Medical’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ICU Medical's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ICU Medical's additional paid-in capital?
ICU Medical (ICUI) reported additional paid-in capital of $1.47B in Q1 2026.
How has ICU Medical's additional paid-in capital changed year-over-year?
ICU Medical's additional paid-in capital increased by 3.5% year-over-year, from $1.42B to $1.47B.
What is the long-term trend for ICU Medical's additional paid-in capital?
Over 5 years (2020 to 2025), ICU Medical's additional paid-in capital has grown at a 16.2% compound annual growth rate (CAGR), from $693.07M to $1.47B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.